Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients

Transplant Infectious Disease

Volumn 12, Issue 3, 2010, Pages 195-203

  Pescovitz, M D ^a   Ettenger, R B ^b   Strife, C F ^c   Sherbotie, J R ^d   Thomas, S E ^e   McDiarmid, S ^a   Bartosh, S ^f   Ives, J ^g   Bouw, M R ^g   Bucuvalas, J ^c  

^a INDIANA UNIVERSITY   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Ganciclovir; Kidney transplant; Liver transplant; Pediatric; Pharmacokinetics; Valganciclovir

Indexed keywords

CREATININE; GANCICLOVIR; LIVER ENZYME; VALGANCICLOVIR; ANTIVIRUS AGENT;

ADOLESCENT; ALGORITHM; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BODY SURFACE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FEMALE; GRAFT RECIPIENT; GROUPS BY AGE; HUMAN; KIDNEY DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEWBORN; PHARMACOKINETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VOMITING; ADULT; ANALOGS AND DERIVATIVES; BLOOD; CYTOMEGALOVIRUS INFECTIONS; DOSE RESPONSE; INFANT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALGORITHMS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BODY SURFACE AREA; CHILD; CHILD, PRESCHOOL; CREATININE; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GANCICLOVIR; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; YOUNG ADULT;

EID: 77950510829     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00478.x     Document Type: Article

References (22)

1. Snydman R. Epidemiology of infections after solid-organ transplantation. Clin Infect Dis 2001 33 (Suppl 1) : S5 S8.
2. Noble S, Faulds D. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998 56 (1) : 115 146.
3. Flechner SM, Avery RK, Fisher R, et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998 66 : 1682 1688.
4. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997 64 (12) : 1843 1846.
5. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000 44 : 2811 2815.
6. McDiarmid SV, Jordan S, Kim GS, et al. Prevention and pre-emptive therapy of post-transplant lympho-proliferative disease in pediatric liver transplant recipients. Transplantation 1998 66 (12) : 1604 1611.
7. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005 44 (5) : 495 507.
8. Pescovitz MD, Jain A, Robson R, Mulgaonkar S, Freeman R, Bouw MR. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant Proc 2007 39 : 3111 3116.
9. Daschner M. Drug dosage in children with reduced renal function. Pediatr Nephrol 2005 20 (12) : 1675 1686.
10. Sharkey I, Boddy AV, Wallace H, Mycroft J, Hollis R, Picton S. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer 2001 85 (1) : 23 28.
11. Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002 38 (13) : 1677 1684.
12. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984 104 (6) : 849 854.
13. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987 317 (17) : 1098.
14. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985 107 (3) : 317 329.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 (1) : 31 41.
16. Vaudry W, Ettenger R, Jara P, et al. on behalf of the WV16726 Study Group. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009 9 (3) : 636 643.
17. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999 39 (8) : 800 804.
18. Trang JM, Kidd L, Gruber W, et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Clin Pharmacol Ther 1993 53 (1) : 15 21.
19. Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994 48 (3) : 455 484.
20. Pescovitz MD, Brook B, Jindal RM, Leapman SB, Milgrom ML, Filo RS. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. Clin Transplant 1997 11 (6) : 613 617.
21. Jacqz-Aigrain E, Macher MA, Sauvageon-Marthe H, Brun P, Loirat C. Pharmacokinetics of ganciclovir in renal transplant children. Pediatr Nephrol 1992 6 (2) : 194 196.
22. Seikaly MG, Loleh S, Rosenblum A, Browne R. Validation of the Center for Medicare and Medicaid Services algorithm for eligibility for dialysis. Pediatr Nephrol 2004 19 : 893 897.